Anavex Life Sciences Corp (AVXL)

[georgejjl]

For the Phase 2b/3 trial using Blarcamesine to treat early stage Alzheimer's disease, I expect that at both the high and low doses Blarcamesine will prove better than the placebo group for all participants with wild type sigmar1 genes. (non mutant sigmar1). that represents 80% to 90% of those in the trial on average.

The high dose group with wild type sigmar1 and APOE3 alleles (normal APOE3) will not only beat the current standard of care, but actually allow the participants to improve over time.

https://investorshub.advfn.com/uimage/uploads/2020/4/24/ehctfPeerReviewClinicalDataFig3.png

Good luck and GOD bless,